ABSTRACT NUMBER: ESOC2026A1362 GENETICALLY PROXIED INHIBITION OF ANGIOTENSINOGEN SYNTHESIS AND CARDIO- AND CEREBROVASCULAR OUTCOMES
Panagiotis Zangas, Murad Omarov, Lanyue Zhang, Marios Georgakis · 2026
Read ABSTRACT NUMBER: ESOC2026A1362 GENETICALLY PROXIED INHIBITION OF ANGIOTENSINOGEN SYNTHESIS AND CARDIO- AND CEREBROVASCULAR OUTCOMES by Panagiotis Zangas, Murad Omarov, Lanyue Zhang, Marios Georgakis (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146195.txt.
Description
Panagiotis Zangas and co-authors report a 2026 conference study using genes to mimic a new class of blood pressure drugs. The drugs block the making of a hormone that tightens vessels. Gene variants that copy the drug effect let the team preview long-term gains and risks.
Variants tied to lower hormone levels also tracked with lower blood pressure, as the drugs cause. The same gene pattern tied to lower odds of heart artery disease, stroke, and heart failure. Links extended to bleeding stroke, vessel dementia signs, and neck plaque on scans. Each gain was scaled to a one-point drop in upper pressure. The authors say the pattern makes a case for full trials of the drug class.
Catalog record
| CREATOR | Panagiotis Zangas, Murad Omarov, Lanyue Zhang, Marios Georgakis |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |